Genetic ablation or pharmacological disruption of TRPV1 attenuates airway injury and asthma in murine models of allergic airway inflammation (Rehman et al. 2013; Mabalirajan et al. 2013) while TRPV1 denervation decreases dendritic cell numbers in response to antigenic challenge (Kradin et al. 1997). The gene discussed is TRPV1; the disease is asthma.